Express Healthcare

Varco Leg Care secures $0.5 million seed funding

0 249

The recently-concluded seed round was led by Sunicon Maiden Fund, an early-stage venture fund curated by Sunicon Ventures

New Delhi-based Varco Leg Care, leg care brand, has raised a cumulative of US$ 0.5 Million (over Rs 4.5 crore) in seed funding, while doubling its valuation within a span of only 10 months. The recently-concluded seed round was led by Sunicon Maiden Fund, an early-stage venture fund curated by Sunicon Ventures.

Varco Leg Care will be utilising the newly-acquired seed capital to strategically bolster capabilities across various fronts, which include enhancing offline touchpoints, advancing research and development (R&D) initiatives, and scaling and optimising marketing efforts. Additionally, the company would be allocating significant funds and resources in the near future towards enhancing its credibility furthermore with expansion of its existing IP portfolio (4 patents have been filed by Varco till date), as well as publishing its in-house conducted clinical studies’ findings in various reputable medical journals.

Speaking about the latest fundraise, Anondeep Ganguly, CEO, Varco Leg Care said, “We are elated to announce our seed fundraise led by Sunicon Maiden Fund, signifying their strong vote of confidence in Varco’s groundbreaking approach to leg health management. This capital infusion serves as a major milestone in our growth journey; it not just propels us in boosting our customer base, supply chain and offline visibility, but will also be playing a pivotal role in advancing our steadfast commitment to presenting robust clinical evidence-based research and solutions. We are not only emphasizing and focusing on extensive clinical trials, but also leveraging a pioneering low-friction technology to establish and validate that evidence. Going ahead, as we grow and scale exponentially and remain committed to delivering superlative leg health solutions, we shall continue placing the needs of our valued customers at the heart of our R&D initiatives”.

 

 

- Advertisement -

Leave A Reply

Your email address will not be published.